The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
Open accessAbstract
Chemotherapeutic drugs are cytotoxic by induction of apoptosis in drug-sensitive cells. We investigated the mechanism of bleomycin-induced cytotoxicity in hepatoma cells. At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2). Bleomycin did not increase CD95 in hepatoma cells with mutated p53 (Huh7) or in hepatoma cells which were p53-/- (Hep3B). In addition, sensitivity towards CD95-mediated apoptosis was also increased in wt p53 positive HepG2 cells. Microinjection of wt p53 cDNA into HepG2 cells had the same effect. In contrast, bleomycin did not enhance susceptibility towards CD95-mediated apoptosis in Huh7 and in Hep3B cells. Furthermore, bleomycin treatment of HepG2 cells increased CD95 ligand (CD95L) mRNA expression. Most notably, bleomycin-induced apoptosis in HepG2 cells was almost completely inhibited by antibodies which interfere with CD95 receptor/ligand interaction. These data suggest that apoptosis induced by bleomycin is mediated, at least in part, by p53-dependent stimulation of the CD95 receptor/ligand system. The same applies to other anti-cancer drugs such as cisplatin and methotrexate. These data may have major consequences for drug treatment of cancer and the explanation of drug sensitivity and resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., & Riccardi, C. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90198-o · Cited by 4,579
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 1×
“On the other hand, bcl-2 and its antagonist bax have been shown to be regulated by p53 (68, 69).”
BackgroundParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81266-0 · Cited by 3,046 · cited 1×
“The death domain of the receptor binds to the death domain of the adapter molecule FADD, which binds and activates FLICE to generate the most apical enzymatic component of a death cascade composed of other ICE/CED-3 family members (61).”
BackgroundSelf-citationp53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,737
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00245.x · Cited by 2,184
Self-citationTumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K.-M., & Krammer, P. H. (1989) · Science · doi:10.1126/science.2787530 · Cited by 1,716
Self-citationAutocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Self-citationFas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line
Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I., & Knowles, B. B. (1979) · Nature · doi:10.1038/282615a0 · Cited by 1,317
Apoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
Self-citationInteraction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen
Smith, M. L., Chen, I.-T., Zhan, Q., Bae, I., Chen, C.-Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M., & Fornace, A. J. (1994) · Science · doi:10.1126/science.7973727 · Cited by 944
Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes.
Sellins, K. S., & Cohen, J. J. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.10.3199 · Cited by 921
Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
Gordon Steel, G., & Peckham, M. J. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90044-0 · Cited by 908
Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis.
Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H., & Cory, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00304.x · Cited by 784
Self-citationInduction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.
Fritsche, M., Haessler, C., & Brandner, G. (1993) · PubMed · Cited by 747
Involvement of an ICE-like protease in Fas-mediated apoptosis
Enari, M., Hug, H., & Nagata, S. (1995) · Nature · doi:10.1038/375078a0 · Cited by 734
Self-citationWild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734
Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., et al. (1996) · Nature Medicine · doi:10.1038/nm0996-985 · Cited by 703
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., & Runkel, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1223 · Cited by 692
Self-citationLoss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
Wahl, A. F., Donaldson, K. L., Faircnild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., & Galloway, D. A. (1996) · Nature Medicine · doi:10.1038/nm0196-72 · Cited by 646
Fraser, A., & Evan, G. (1996) · Cell · doi:10.1016/s0092-8674(00)81005-3 · Cited by 638
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis
Los, M., Craen, M. V. D., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Dröge, W., Krammer, P. H., Fiers, W., & Schulze-Osthoff, K. (1995) · Nature · doi:10.1038/375081a0 · Cited by 607
Self-citationBerke, G. (1995) · Cell · doi:10.1016/0092-8674(95)90365-8 · Cited by 501
Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia
Evans, W. E., Crom, W. R., Abromowitch, M., Dodge, R., Look, A. T., Bowman, W. P., George, S. L., & Pui, C.-H. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140803 · Cited by 392
Bcl–2 protects from lethal hepatic apoptosis induced by an ant–Fas antibody in mice
Lacronique, V., Mignon, A., Fabre, M., Viollet, B., Rouquet, N., Molina, T., Porteu, A., Henrion, A., Bouscary, D., Varlet, P., et al. (1996) · Nature Medicine · doi:10.1038/nm0196-80 · Cited by 369
Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
Bardeesy, N., Falkoff, D., Petruzzi, M.-J., Nowak, N., Zabel, B., Adam, M., Aguiar, M. C., Grundy, P., Shows, T., & Pelletier, J. (1994) · Nature Genetics · doi:10.1038/ng0594-91 · Cited by 339
p53 in signaling checkpoint arrest or apoptosis
Bates, S., & Vousden, K. H. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90004-0 · Cited by 331
Regulation of apoptosis in the immune system
Krammer, P. H., Behrmann, I., Daniel, P., Dhein, J., & Debatin, K.-M. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90102-3 · Cited by 308
Self-citationLotem, J., & Sachs, L. (1993) · Blood · doi:10.1182/blood.v82.4.1092.1092 · Cited by 301
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Hawkins, D. S., Demers, G. W., & Galloway, D. A. (1996) · PubMed · Cited by 297
Jäättelä, M., Benedict, M., Tewari, M., Ja, S., & Dixit, V. (1995) · PubMed · Cited by 289
Harris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., & Krammer, P. H. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.10.3166 · Cited by 278
Self-citationInteractions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271
Owen‐Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K. K., & Yonehara, S. (1994) · PubMed · Cited by 258
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines
Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., & Harris, C. C. (1993) · Carcinogenesis · doi:10.1093/carcin/14.5.987 · Cited by 241
Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways.
Wong, G. H. W., & Goeddel, D. V. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.4.1751 · Cited by 193
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Shea, T. C., Flaherty, M., Elias, A., Eder, J. P., Antman, K., Begg, C., Schnipper, L., Frei, E., & Henner, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.651 · Cited by 188
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood
Wada, M., Bartram, C., Nakamura, H., Hachiya, M., Chen, D., Borenstein, J., Miller, C., Ludwig, L., Hansen-Hagge, T., & Ludwig, W. (1993) · Blood · doi:10.1182/blood.v82.10.3163.3163 · Cited by 178
Nakabayashi, H., Taketa, K., Yamane, T., Miyazaki, M., Miyano, K., & Sato, J. (1984) · PubMed · Cited by 133
Ponchel, F., Puisieux, A., Tabone, É., Michot, J., Fröschl, G., Morel, A., Frébourg, T., Fontanière, B., Oberhammer, F., & Öztürk, M. (1994) · PubMed · Cited by 95
Wu, G. S., & El‐Deiry, W. S. (1996) · Nature Medicine · doi:10.1038/nm0396-255a · Cited by 90
Assignment of the human fas antigen gene (FAS) to 10q24.1
Inazawa, J., Itoh, N., Abe, T., & Nagata, S. (1992) · Genomics · doi:10.1016/s0888-7543(05)80200-9 · Cited by 86
Shifting the cancer paradigm: must we kill to cure?
Schipper, H., Goh, C., & Wang, T. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.801 · Cited by 76
CD95 (APO-1/Fas)-associating signalling proteins.
Peter, M. E., Kischkel, F. C., Hellbardt, S., Chinnaiyan, A. M., Krammer, P. H., & Dixit, V. M. (1996) · PubMed · Cited by 75
Self-citationVolkmann, M., Müller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Räth, U., Kommerell, B., Zentgraf, H., & Galle, P. R. (1993) · Hepatology · doi:10.1002/hep.1840180313 · Cited by 70
Self-citationPeter, M. E., Dhein, J., Ehret, A., Hellbardt, S., Walczak, H., Moldenhauer, G., & Krammer, P. H. (1995) · International Immunology · doi:10.1093/intimm/7.11.1873 · Cited by 64
Self-citationMenon, S. D., Guy, G. R., & Tan, Y. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18881 · Cited by 63
Muller, C., Chatelut, É., Gualano, V., Forni, M. D., Huguet, F., Attal, M., Canal, P., & Laurent, G. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00735923 · Cited by 60
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis???
McCarty, L. (1990) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-199005000-00002 · Cited by 42
Bleomycin clinical pharmacology by radioimmunoassay
Hall, S. W., Strong, J. E., Broughton, A., Frazier, M. L., & Benjamin, R. S. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00296756 · Cited by 38
Significance of spontaneous apoptosis during colorectal tumorigenesis
Koike, M. (1996) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199606)62:2<135::aid-jso10>3.0.co;2-7 · Cited by 35
Delia, D., Mizutani, S., Lamorte, G., Goi, K., Iwata, S., & Pierotti, M. A. (1996) · Nature Medicine · doi:10.1038/nm0796-724 · Cited by 32
Cited by
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
“To t his end, treatment with anticancer drugs triggered an increase in CD95L expression, which stimulated the receptor pathway in an autocrine or paracrine manner by binding to its receptor CD95 (Friesen et al., 1996; Fulda et al., 1997, 1998a; Houghton et al., 1997; Muller et al., 1997).”
BackgroundMethodDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Self-citationA Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
Induction of Apoptosis by Cancer Chemotherapy
Kaufmann, S. H., & Earnshaw, W. C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4838 · Cited by 1,266
Reed, J. C. (1998) · Oncogene · doi:10.1038/sj.onc.1202591 · Cited by 1,049
Metadata
- Authors
- Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-02-01
- Volume
- 99
- Issue
- 3
- Pages
- 403-413
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2111714805
- Cited by
- 748
- References
- 69
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.